---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-142278"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T13:57:47.043108+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024

## Summary
- Acquisition of Alpine for approximately $5.0B in equity value completed.
- Alpine now operates as a wholly owned subsidiary of Vertex.
- Accounting treatment for the acquisition to be finalized during Q2 2024.
- Merger effected via tender offer followed by a Section 251(h) merger.

## SEC filing metadata
- accession: 0001193125-24-142278
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000119312524142278/0001193125-24-142278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000119312524142278/d818729d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-142278
- JSON: https://secwatch.observer/filing/0001193125-24-142278.json
- Plain text: https://secwatch.observer/filing/0001193125-24-142278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.